Torbay and South Devon
NHS Foundation Trust

Email: foi.tsdft@nhs.net
Our Ref: TSD10918

2 November 2026

Dear Sir/Madam

Request for Information

We are writing to confirm that we have now completed our search for the information you requested.

A copy of the information is below:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

Avelumab + Axitinib	<5
Axitinib	<5
Cabozantinib	9
Everolimus	0
Lenvatinib + Everolimus	6
Lenvatinib + Pembrolizumab	0
Nivolumab monotherapy	<5
Nivolumab + Cabozantinib	<5
Nivolumab + Ipilimumab	<5
Pazopanib	<5
Pembrolizumab monotherapy	<5
Pembrolizumab + Axitinib	0
Radiotherapy only	0
Sunitinib	<5
Temsirolimus	0
Tivozanib	0
Other active systemic anti-cancer therapy	0
Palliative care only	33
Pembrolizumab (solution for subcutaneous injection)	0

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

Avelumab + Axitinib (Bavencio + Inlyta)	<5
Cabozantinib (Cometriq)	5
Nivolumab (Opdivo)	0
Nivolumab + Cabozantinib (Opdivo + Cometriq)	<5
Nivolumab + Ipilimumab (Opdivo + Yervoy)	<5
Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)	0
Pembrolizumab + Axitinib	0

This information is not held in a readily accessible format. Answering this question would require an individual review of patient records, exceeding the cost limit under section 12 of the Freedom of Information Act.

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma? 9 in total

Nivolumab (monotherapy)	
Nivolumab + Ipilimumab	
Nivolumab + Cabozantinib	
Avelumab + Axitinib	
Lenvatinib + Everolimus	
Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)	
Cabozantinib (Cometriq)	
Pembrolizumab + Axitinib	

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**
This information is not held in a readily accessible format. Answering this question would require an individual review of patient records, exceeding the cost limit under section 12 of the Freedom of Information Act.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Procedure Opcs	Count of Procedures
M021	11
M022	8
M023	<5
M025	12
M039	16
M104	6

Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

We do not currently have any renal trials open to recruitment.

Currently we have 2 studies closed to recruitment and now in follow up:-

- **RAMPART** – *Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse* – 5 patients recruited.

- **Modify** – *A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer* – there was a renal arm to this as well as a H&N arm – <5 patients recruited to the Renal arm.

Low Numbers:

Where there are less than 5, we are unable to provide the exact information you require as this may enable the identification of our employees, members of the public or patients. This would constitute personal information and would be considered exempt under Section 40 of the Freedom of Information Act. Section 40 (FOI Act) provides an exemption to disclosure, where disclosure would contravene any of the Data Protection principles. This exemption is an absolute exemption that is not subject to the public interest test. Where the information relates to an individual who can be identified from that data, or from that data when added to other information, in the possession of, or likely to come into the possession of the data controller, this meets the definition of personal data as defined by the Data Protection Act.

The information supplied to you continues to be protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting.

If you wish to discuss any of the above, please contact us, quoting the FOI reference number above.

If you are unhappy with the way in which we have handled your request, please contact the Data Protection and Freedom of Information Lead in the first instance. If you wish to make a formal complaint, you should write to our Information Governance Team at Information Governance and Data Protection, Belmont Court, Torbay and South Devon NHS Foundation Trust, Torquay, TQ2 7AA or by email to tsdft.igteam@nhs.net

If you are not content with the outcome of your complaint or the internal review, you may apply directly to the Information Commissioner for a decision. Generally, the Information Commissioner will only make a decision once you have exhausted the complaints and/or internal review process provided by us. The Information Commissioner can be contacted

at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF or through this link https://ico.org.uk/global/contact-us/

Yours sincerely,

Freedom of Information Team